Search research articles
Contact Us
Filters
Showing results (31-40 of 112) with videos related to
Page
of 12
Sort By:
Cancer
|
November 15, 1981
Evaluation of alternating chemotherapy and sites and extent of disease in extensive small cell lung cancer
T R Lininger, T R Fleming, R T Eagan
Seminars in Oncology
|
April 1, 1988
Surgical adjuvant therapy of rectal cancer
M J O'Connell, L L Gunderson, T R Fleming
Investigational New Drugs
|
February 1, 1990
Phase II evaluation of esorubicin (4'deoxydoxorubicin) in pancreatic adenocarcinoma: a Southwest Oncology Group study
C B Vaughn, S E Salmon, T R Fleming
Biometrics
|
December 1, 1995
Diagnostic plots to reveal functional form for covariates in multiplicative intensity models
P M Grambsch, T M Therneau, T R Fleming
Controlled Clinical Trials
|
March 1, 1984
Considerations for monitoring and evaluating treatment effects in clinical trials
T R Fleming, S J Green, D P Harrington
Statistics in Medicine
|
July 15, 1997
Estimating the proportion of treatment effect explained by a surrogate marker
D Y Lin, T R Fleming, V De Gruttola
Controlled Clinical Trials
|
December 1, 1984
Designs for group sequential tests
T R Fleming, D P Harrington, P C O'Brien
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 1, 1987
Policies for study monitoring and interim reporting of results
S J Green, T R Fleming, J R O'Fallon
Cancer Treatment Reports
|
December 1, 1987
Cisplatin, vinblastine, and mitoguazone in squamous cell carcinoma of the esophagus: a Southwest Oncology Group Study
R Chapman, T R Fleming, J Van Damme, et al.
Statistics in Medicine
|
May 15, 1994
Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research
T R Fleming, R L Prentice, M S Pepe, et al.
Page
of 12
Search research articles
Search
Showing results (31-40 of 112) with videos related to
Sort By:
Page
of 12
Cancer
|
November 15, 1981
Evaluation of alternating chemotherapy and sites and extent of disease in extensive small cell lung cancer
T R Lininger, T R Fleming, R T Eagan
Seminars in Oncology
|
April 1, 1988
Surgical adjuvant therapy of rectal cancer
M J O'Connell, L L Gunderson, T R Fleming
Investigational New Drugs
|
February 1, 1990
Phase II evaluation of esorubicin (4'deoxydoxorubicin) in pancreatic adenocarcinoma: a Southwest Oncology Group study
C B Vaughn, S E Salmon, T R Fleming
Biometrics
|
December 1, 1995
Diagnostic plots to reveal functional form for covariates in multiplicative intensity models
P M Grambsch, T M Therneau, T R Fleming
Controlled Clinical Trials
|
March 1, 1984
Considerations for monitoring and evaluating treatment effects in clinical trials
T R Fleming, S J Green, D P Harrington
Statistics in Medicine
|
July 15, 1997
Estimating the proportion of treatment effect explained by a surrogate marker
D Y Lin, T R Fleming, V De Gruttola
Controlled Clinical Trials
|
December 1, 1984
Designs for group sequential tests
T R Fleming, D P Harrington, P C O'Brien
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 1, 1987
Policies for study monitoring and interim reporting of results
S J Green, T R Fleming, J R O'Fallon
Cancer Treatment Reports
|
December 1, 1987
Cisplatin, vinblastine, and mitoguazone in squamous cell carcinoma of the esophagus: a Southwest Oncology Group Study
R Chapman, T R Fleming, J Van Damme, et al.
Statistics in Medicine
|
May 15, 1994
Surrogate and auxiliary endpoints in clinical trials, with potential applications in cancer and AIDS research
T R Fleming, R L Prentice, M S Pepe, et al.
Page
of 12